0 1 A a DT 2 5 low low JJ 6 13 NM23.H1 nm23.h1 NN 14 18 gene gene NN 19 29 expression expression NN 30 41 identifying identify VBG 42 46 high high JJ 47 57 malignancy malignancy NN 58 63 human human JJ 64 73 melanomas melanoma NNS 73 74 . . . 76 79 The the DT 80 84 NM23 nm23 NN 85 89 gene gene NN 90 93 has have VBZ 94 98 been be VBN 99 107 proposed propose VBN 108 110 as as IN 111 112 a a DT 113 134 metastasis-suppressor metastasis-suppressor NN 135 139 gene gene NN 139 140 , , , 141 144 and and CC 145 148 its its PRP$ 149 152 use use NN 153 156 has have VBZ 157 161 been be VBN 162 171 suggested suggest VBN 172 174 as as IN 175 185 prognostic prognostic JJ 186 192 factor factor NN 192 193 . . . 194 198 NM23 NM23 NNP 199 202 was be VBD 203 213 identified identify VBN 214 216 in in IN 217 218 a a DT 219 225 system system NN 226 228 of of IN 229 235 murine murine JJ 236 244 melanoma melanoma NN 245 249 cell cell NN 250 255 lines line NNS 255 256 , , , 257 259 in in IN 260 265 which which WDT 266 268 an an DT 269 276 inverse inverse JJ 277 289 relationship relationship NN 290 293 was be VBD 294 299 found find VBN 300 307 between between IN 308 312 NM23 nm23 NN 313 323 expression expression NN 324 327 and and CC 328 338 metastatic metastatic JJ 339 346 ability ability NN 346 347 . . . 348 350 In in IN 351 352 a a DT 353 358 human human JJ 359 368 malignant malignant JJ 369 377 melanoma melanoma NN 378 383 study study NN 384 388 NM23 nm23 NN 389 399 expression expression NN 400 403 was be VBD 404 409 found find VBN 410 412 to to TO 413 415 be be VB 416 429 significantly significantly RB 430 435 lower low JJR 436 438 in in IN 439 449 metastases metastasis NNS 450 454 that that WDT 455 464 developed develop VBD 465 469 less less JJR 470 474 than than IN 475 477 24 24 CD 478 484 months month NNS 485 490 after after IN 491 500 diagnosis diagnosis NN 501 503 of of IN 504 507 the the DT 508 515 primary primary JJ 516 523 tumours tumour NNS 523 524 . . . 525 528 The the DT 529 536 present present JJ 537 542 paper paper NN 543 550 studies study NNS 551 554 the the DT 555 565 expression expression NN 566 568 of of IN 569 572 the the DT 573 580 NM23.H1 nm23.h1 NN 581 585 gene gene NN 586 588 in in IN 589 593 cell cell NN 594 599 lines line NNS 600 605 which which WDT 606 612 derive derive VBP 613 617 from from IN 618 625 primary primary JJ 626 628 or or CC 629 639 metastatic metastatic JJ 640 645 human human JJ 646 655 malignant malignant JJ 656 665 melanomas melanoma NNS 666 668 in in IN 669 677 relation relation NN 678 680 to to TO 681 688 staging staging NN 688 689 , , , 690 702 infiltration infiltration NN 703 709 degree degree NN 709 710 , , , 711 722 lymphocytic lymphocytic JJ 723 735 infiltration infiltration NN 735 736 , , , 737 741 cell cell NN 742 752 morphology morphology NN 752 753 , , , 754 758 cell cell NN 759 771 pigmentation pigmentation NN 771 772 , , , 773 782 karyotype karyotype NN 782 783 , , , 784 787 and and CC 788 800 disease-free disease-free JJ 801 809 survival survival NN 809 810 . . . 811 814 The the DT 815 820 level level NN 821 823 of of IN 824 828 mRNA mrna NN 829 839 expression expression NN 840 842 of of IN 843 846 the the DT 847 851 NM23 nm23 NN 852 856 gene gene NN 857 859 is be VBZ 860 873 significantly significantly RB 874 879 lower low JJR 880 882 in in IN 883 887 cell cell NN 888 893 lines line NNS 894 898 that that WDT 899 905 derive derive VBP 906 910 from from IN 911 915 more more RBR 916 928 infiltrating infiltrate VBG 929 936 primary primary JJ 937 946 melanomas melanoma NNS 947 951 than than IN 952 954 in in IN 955 959 cell cell NN 960 965 lines line NNS 966 974 obtained obtain VBN 975 979 from from IN 980 984 less less JJR 985 997 infiltrating infiltrating JJ 998 1005 tumours tumour NNS 1005 1006 . . . 1007 1015 Moreover moreover RB 1015 1016 , , , 1017 1021 cell cell NN 1022 1027 lines line NNS 1028 1035 derived derive VBN 1036 1040 from from IN 1041 1048 tumours tumour NNS 1049 1051 of of IN 1052 1060 patients patient NNS 1061 1065 with with IN 1066 1067 a a DT 1068 1080 disease-free disease-free JJ 1081 1089 survival survival NN 1090 1092 of of IN 1093 1097 more more JJR 1098 1102 than than IN 1103 1105 24 24 CD 1106 1112 months month NNS 1113 1114 ( ( ( 1114 1119 24-58 24-58 CD 1120 1126 months month NNS 1126 1127 ) ) ) 1128 1135 express express VBP 1136 1139 the the DT 1140 1144 NM23 nm23 NN 1145 1149 gene gene NN 1150 1152 at at IN 1153 1159 higher high JJR 1160 1166 levels level NNS 1167 1171 than than IN 1172 1176 cell cell NN 1177 1182 lines line NNS 1183 1191 obtained obtain VBN 1192 1196 from from IN 1197 1206 melanomas melanoma NNS 1207 1209 of of IN 1210 1218 patients patient NNS 1219 1223 with with IN 1224 1225 a a DT 1226 1238 disease-free disease-free JJ 1239 1247 survival survival NN 1248 1250 of of IN 1251 1255 less less JJR 1256 1260 than than IN 1261 1263 24 24 CD 1264 1270 months month NNS 1271 1272 ( ( ( 1272 1276 6-15 6-15 CD 1277 1283 months month NNS 1283 1284 ) ) ) 1284 1285 . . .